GOVX - Covid-19 Vaccination Update

Developing a vaccine against Covid19 is of obvious global importance. Vaccines stimulate immune systems to produce antibodies, similar to the subject being exposed to the disease. Production of antibodies and stimulation of immune systems help the human body to develop immunity against disease. This provides a preventative measure of protection. As it relates to the novel coronavirus, several approaches (Exhibit 1) are being investigated by scientists in the biotechnology and pharmaceutical industry, hospitals, and academic research institutes. Each approach holds different advantages and disadvantages. For example, the RNA and DNA-based vaccines are leading in their clinical advancement due to advantages in the speed of development. However, their safety profile is not well defined, and these vaccines could run into potential hurdles and face stricter regulatory approvals. Two US-based companies are currently in clinical trials, the first vaccine into the clinic was Moderna’s mRNA-1273 on March 16th, followed by Inovio’s DNA vaccine on April 6th. Read More >>